Skip to main content

Back to Cancer Australia's website

Australian Government - Cancer Australia
Home

Search form

EdCaN - learning resources for nurses

  • EdCaN learning resources
  • Professional development
  • About EdCaN
  • Contact us

Search form

  • Overview
  • Overview of targeted therapies
  • Categories
  • Administration principles
  • Adverse effects
  • Challenges
  • References
  1. EdCaN learning resources
  2. Supporting resources
  3. Targeted therapies
  4. References
  • Printer-friendly version
  • A|A

References

  • Using the EdCaN resources
  • Case-based learning resources
  • Supporting resources
    • The cancer journey
    • Population health concepts
    • The biology of cancer
    • Cancer treatment planning
    • Surgery
    • Radiotherapy
    • Antineoplastic agents
    • Targeted therapies
      • Overview
      • Overview of targeted therapies
      • Categories
      • Administration principles
      • Adverse effects
      • Challenges
      • References
    • Stem cell transplantation
    • Supportive care
    • Aboriginal and Torres Strait Islander peoples
  • Entry to specialty program
  1. National Cancer Institute. Targeted Cancer Therapies. 2014 November 2014; Available from: http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted.
  2. Polovich, M., J.M. White, and L.O. Kelleher, Chemotherapy and biotherapy guidelines and recommendations for practice. 2nd ed. 2005, Pittsburgh: Oncology Nursing Society.
  3. Rieger, P.T., Biotherapy, in Biotherapy: A Comprehensive Overview, P.T. Rieger, Editor. 2001, Jones and Bartlett: Sudbury. p. 3-37.
  4. Hanahan, D. and Robert A. Weinberg, Hallmarks of Cancer: The Next Generation. Cell, 2011. 144(5): p. 646-674.
  5. Brown, M.P. and N. Burdett, Targeted therapies, aspects of pharmaceutical and oncological management. Cancer Forum, 2013. 37(1).
  6. Levitzki, A. and S. Klein, Signal transduction therapy of cancer. Molecular Aspects of Medicine, 2010. 31: p. 287-327.
  7. Liauw, W.S., Molecular mechanisms and clinical use of targeted anticancer drugs. Australian Prescriber, 2013. 36(4): p. 126-131.
  8. National Cancer Institute. Cancer Vaccines. 2014 November 2014; Available from: http://www.cancer.gov/cancertopics/factsheet/Therapy/cancer-vaccines.
  9. Polovich, M., J. Whitford, and N. Olsen, eds. Chemotherapy and biotherapy guidelines and recommendations for practice. 3rd ed. 2009, Oncology Nursing Society: Philadelphia.
  10. Battiato, L.A. and V.S. Wheeler, Biologic and targeted therapy, in Cancer Nursing Principles and Practice, C.H. Yarbro, D. Wujcik, and B. Holmes Gobel, Editors. 2011, Jones and Bartlett: Sudbury.
  11. Solomon, B. and J. Zalcberg, Overview: progress in targeted therapies for cancer. Cancer Forum, 2008. 32: p. 131-135.
  12. Wilkes, G.M. and M. Barton-Burke, Oncology Nursing Drug Handbook. 2010, Boston: Jones and Bartlett Publishers.
  13. Gobel, B.H., Hematopoietic therapy, in Cancer Nursing Principles and Practice, C.H. Yarbro, M.H. Frogge, and M. Goodman, Editors. 2011, Jones and Bartlett: Sudbury. p. 575-589.
  14. Schmidt, K.V. and B.A. Wood, Trends in cancer therapy: Role of monoclonal antibodies. Seminars in Oncology Nursing, 2003. 19: p. 169-179.
  15. Davis, I.D., Update on monoclonal antibodies for the treatment of cancer. Asia-Pacific Journal of Clinical Oncology, 2011. 7(Suppl. 1): p. 20-25.
  16. Gale, D.M., Molecular targets in cancer therapy. Seminars in Oncology Nursing, 2003. 19: p. 193-205.
  17. Boyle, F., Search for the holy grail: Evolving targeted therapies in breast cancer. Cancer Forum, 2008. 32(3): p. 159-162.
  18. Muehlbauer, P.M. and D.J. Schwartzentruber, Cancer vaccines. Seminars in Oncology Nursing, 2003. 19: p. 206-216.
  19. Smith, M., Update on HPV vaccination in Australia. Cancer Forum, 2014. 38(3): p. 207-208.
  20. Muehlbauer, P.M., Anti-angiogenesis in cancer therapy. Seminars in Oncology Nursing, 2003. 19: p. 180-192.
  21. Gasparini, G., The rationale and future potential of angiogenesis inhibitors in neoplasia. Drugs, 1999. 58(1): p. 17-38.
  22. Wilkes, G.M., Targeted cancer therapy: A handbook for nurses. 2011, Sudbury: Jones and Bartlett.
  23. Malizzia, L.J. and A. Hsu, Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma. Clinical Journal of Oncology Nursing, 2008. 12: p. 639-646.
  24. Pook, D. and I.D. Davis, Targeted therapies in renal cell carcinoma. Cancer Forum, 2008. 32(3): p. 155-158.
  25. Stull, D.M., Targeted therapies for the treatment of leukaemia. Seminars in Oncology Nursing, 2003. 19: p. 90-97.
  26. National Institute for Occupational Safety and Health. Preventing occupational exposure to antineoplastic and other hazardous drugs in health care settings. 2004 01.05.2009; Available from: http://www.cdc.gov/niosh/docs/2004-165/.
  27. Alexander, M., et al., Australian consensus guidelines for the safe handling of monoclonal antibodies for cancer treatment by healthcare personnel. Internal Medicine Journal, 2014. 44(10): p. 1018-1026.
  28. Ault, P., Overview of second generation tyrosine kinase inhibitors for patients with imatinib-resistant chronic myeloid leukaemia. Clinical Journal of Oncology Nursing, 2007. 11: p. 125-129.
  29. Meijerman, I., J.H. Beijnen, and J.H.M. Schellens, Herb-Drug Interactions in Oncology: Focus on Mechanisms of Induction. The Oncologist, 2006. 11(7): p. 742-752.
  30. Lohr, L.K., Drug interactions with newer oral chemotherapy agents. US Pharmacist, 2009. 24(7 (Oncology supplement)): p. 4-8.
  31. Breslin, S., Cytokine release syndrome: Overview and nursing implications. Clinical Journal of Oncology Nursing, 2007. 11(Suppl.1): p. 37-42.
  32. Dunsford, J., Nursing management of epidermal growth factor receptor inhibitor-induced toxicities. Clinical Journal of Oncology Nursing, 2008. 12: p. 405-407.
  33. Eaby, B., A. Culkin, and M.E. Lacouture, An interdisciplinary consensus on managing skin reactions associated with human epidermal growth factor receptor inhibitors. Clinical Journal of Oncology Nursing, 2008. 12: p. 283-290.
  34. Viale, P.H. and D.S. Yamamoto, Cardiovascular toxicity associated with cancer treatment. Clinical Journal of Oncology Nursing, 2008. 12: p. 627-638.
  35. Goodrich, A., Emerging therapeutic options for B-cell disorders: idiopathic thrombocytopenic purpura and chronic lymphocytic leukaemia. Clinical Journal of Oncology Nursing, 2007. Suppl. 11: p. 23-36.
  36. Davis, I.D. and J.S. Cebon, Developing cancer immunotherapies. Asia-Pacific Journal of Clinical Oncology, 2011. 7(Suppl. 1): p. 9-13.
  37. Schilsky, R.L., et al., Commentary: tackling the challenges of developing targeted therapies for cancer. The Oncologist, 2010. 15: p. 484-487.
  38. Lord, S., C. Lee, and R.J. Simes, Role of prognostic and predictive markers in cancer. Cancer Forum, 2008. 32(3).
  39. Malinowsky, K., et al., Targeted therapies in cancer - challenges and chances offered by newly developed techniques for protein analysis in clinical tissues. Journal of Cancer, 2011. 2: p. 26-35.
  • Copyright © 2021 - Cancer Australia
  • Contact Us
  • Copyright
  • Disclaimer
  • Privacy policy